- Conditions
- Scleroderma
- Interventions
- atorvastatin, Placebo
- Drug
- Lead sponsor
- Robyn T. Domsic, MD, MPH
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–523
of 523
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obesity, Metabolic Syndrome, Hyperuricemia
- Interventions
- Rasburicase
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Aging, Endothelial Dysfunction, Cardiovascular Function, Arterial Stiffness
- Interventions
- Placebo, Mitoquinone Mesylate
- Dietary Supplement
- Lead sponsor
- Ball State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Muncie, Indiana
- Conditions
- Endothelial Function of Saphenous Vein Grafts
- Interventions
- Use of Maquet Vasoshield Pressure-limiting syringe on SVG, Use of non-regulated syringe on SVG
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Atherosclerosis
- Interventions
- salsalate, placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- Interventions
- AL58805, AL8326, Eribulin, Fulvestrant
- Drug
- Lead sponsor
- Advenchen Pharmaceuticals, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Peripheral Arterial Disease
- Interventions
- L-N^G monomethyl arginine (L-NMMA)
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Parenteral Nutrition
- Interventions
- ClinOleic 20% Intravenous Emulsion, Intralipid, 20% Intravenous Emulsion
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Growth Hormone Deficiency, Panhypopituitarism, Short Stature
- Interventions
- growth hormone
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- High Blood Pressure
- Interventions
- Aliskiren 150 mg, Placebo, HCTZ, Aliskiren 300 mg
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Parkinson Disease (PD)
- Interventions
- Guided Cycling, Non-Contact Boxing, Traditional Physical Therapy Program (Standard of Care)
- Behavioral
- Lead sponsor
- University of Texas, El Paso
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- El Paso, Texas
- Conditions
- Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Female, Adult, Endothelial Function (Reactive Hyperemia), Arterial Stiffness, Cognition, Oxidative Stress, Gut Microbiota, Overweight, Inflammation, Microvascular Function, Body Composition
- Interventions
- Wild Blueberry, Placebo
- Dietary Supplement
- Lead sponsor
- Georgia State University
- Other
- Eligibility
- 20 Years to 65 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Peripheral Arterial Disease
- Interventions
- Pro-Omega, Omega 3 Fatty Acid
- Dietary Supplement
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Mood Disorders, Hypertension, Overweight and Obesity, Vascular Stiffness, Sleep, Elevated Blood Pressure
- Interventions
- Cardiovascular Assessments, Actigraphy, Laboratory assessments, Emotional/ Behavioural assessments
- Diagnostic Test · Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- Up to 22 Years
- Enrollment
- 37 participants
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Cognitive Impairment, Hypertension, Aging
- Interventions
- candesartan, lisinopril, hydrochlorothiazide, nifedipine, long acting, metoprolol, long-acting
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Boston, Massachusetts
- Conditions
- Insulin Resistance
- Interventions
- salsalate, Placebo
- Drug
- Lead sponsor
- Boston University
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Peripheral Vascular Disease, Lipid Disorder, Endothelial Dysfunction
- Interventions
- High Saturated Fat
- Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Wauwatosa, Wisconsin
- Conditions
- HIV, Vascular Diseases, Cardiovascular Diseases, Atherosclerosis, HIV Infections
- Interventions
- Combination antiretroviral therapy (cART), Pentoxifylline, Placebo
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana